PNU-120596, also known as NSC 216666, is α7 nicotinic acetylcholine receptor positive allosteric modulator. PNU-120596 reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates.

Product information

CAS Number: 501925-31-1

Molecular Weight: 311.72

Formula: C13H14ClN3O4

Synonym:

PNU 120596

PNU120596

NSC 216666

NSC-216666

NSC216666

Chemical Name: 1-(5-Chloro-2, 4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea

Smiles: CC1=CC(NC(=O)NC2=CC(Cl)=C(C=C2OC)OC)=NO1

InChiKey: CEIIEALEIHQDBX-UHFFFAOYSA-N

InChi: InChI=1S/C13H14ClN3O4/c1-7-4-12(17-21-7)16-13(18)15-9-5-8(14)10(19-2)6-11(9)20-3/h4-6H,1-3H3,(H2,15,16,17,18)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 62 mg/mL(198.89 mM). Water: Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

PNU-120596 increases agonist (Ach)-evoked calcium flux mediated by an engineered variant of the human α7 nAChR. PNU-120596 increases agonists (choline and ACh)-evoked currents mediated by wild-type receptors and also demonstrates a pronounced prolongation of the evoked response in the continued presence of agonist in Xenopus oocytes. PNU-120596 increases the channel mean open time ofα7 nAChRs but has no effect on ion selectivity and relatively little, if any, effect on unitary conductance. When applied to acute hippocampal slices, PNU-120596 increases the frequency of ACh-evoked GABAergic postsynaptic currents measured in pyramidal neurons; this effect is suppressed by TTX, suggesting that PNU-120596 modulates the function of α7 nAChRs located on the somatodendritic membrane of hippocampal interneurons. Besides the positive modulation to α7 nAChR, PNU-120596 induces a profound retardation of the kinetics of desensitization, raising the potential of Ca2+-induced toxicity through excessive stimulation of α7 nAChR. PNU-120596 causes changes in cysteine accessibility at the inner beta sheet, transition zone and agonist binding site while binding to α7 nAChR. Binding sites for PNU-120596 are not in the agonist-binding sites and PNU-120596 enhances agonist-evoked gating of nicotinic receptors by eliciting conformational effects that are similar but nonidentical to the gating conformations promoted by Ach.

In Vivo:

Systemic administration of PNU-120596 (1 mg/kg) to rats improves the auditory gating deficit caused by amphetamine, a model proposed to reflect a circuit level disturbance associated with schizophrenia. When administered prior to Carrageenan, 30 mg/kg PNU-1230596 significantly blunts mechanical hyperalgesia and weight bearing deficits for up to 4 hours. PNU-120596 attenuates the carrageenan-induced increase in levels of TNF-α and IL-6 within the hindpaw oedema, diclofenac only attenuated IL-6 levels. Established mechanical hyperalgesia induced by Carrageenan or CFA is also partially reversed by PNU-120596.

References:

1. Barron SC, et al, Mol Pharmacol, 2009 76(2), 253-263.
2. Ng HJ, et al, Proc Natl Acad Sci USA, 2007, 104(19), 8059-8064.
3. Hurst RS, et al, J Neurosci, 2005, 25(17), 4396-4405.

Products are for research use only. Not for human use.